Loading...

Nachrichtenliste

The FDA accelerated its approval of Bruton's kinase inhibitor Jaypirca

2023-02-01


The FDA accelerated its approval of Bruton's kinase inhibitor Jaypirca

2023 The first fluorine-containing drug was approved. 2023.01.27 Eli Lilly's Loxo Oncology announced accelerated FDA approval of its BTK inhibitor Jaypirca (pirtobrutinib), For adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least 2-line system therapy after prior treatment including a BTK inhibitor (Jaypirca is the first and currently only non-covalent reversible BTK inhibitor approved by the FDA).

Wir möchten Cookies verwenden, um Ihre Nutzung dieser Website besser zu verstehen und Ihre Erfahrung bei zukünftigen Besuchen der Website zu verbessern. Sie können diese Einstellung in Ihren Browsereinstellungen ändern. Weitere Informationen zur Verwendung von Cookies finden Sie in unserer Datenschutzrichtlinie.